Zobrazeno 1 - 10 of 66 pro vyhledávání: '"Robert S Seitz"'
1
Akademický článek
Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
Autor: Kenichi Harano, Ying Wang, Bora Lim, Robert S Seitz, Stephan W Morris, Daniel B Bailey, David R Hout, Rachel L Skelton, Brian Z Ring, Hiroko Masuda, Arvind U K Rao, Steven Van Laere, Francois Bertucci, Wendy A Woodward, James M Reuben, Savitri Krishnamurthy, Naoto T Ueno
Publikováno v: PLoS ONE, Vol 13, Iss 10, p e0204513 (2018)
In patients with triple-negative breast cancer (TNBC), tumor-infiltrating lymphocytes (TILs) are associated with improved survival. Lehmann et al. identified 4 molecular subtypes of TNBC [basal-like (BL) 1, BL2, mesenchymal (M), and luminal androgen
Externí odkaz: https://doaj.org/article/d68e3061b3564009845c351904eed6a8
Zobrazit plný text záznamu
2
Akademický článek
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
Autor: David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Publikováno v: npj Breast Cancer, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and bioma
Externí odkaz: https://doaj.org/article/0206d7fb11584f5ab468ac8a9e5bed64
Zobrazit plný text záznamu
3
Akademický článek
Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
Autor: Robert S. Seitz, Michael E. Hurwitz, Tyler J. Nielsen, Daniel B. Bailey, Matthew G. Varga, Brian Z. Ring, Carrie F. Metts, Brock L. Schweitzer, Kimberly McGregor, Douglas T. Ross
Publikováno v: Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background The IO Score is a 27-gene immuno-oncology (IO) classifier that has previously predicted benefit to immune checkpoint inhibitor (ICI) therapy in triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). It genera
Externí odkaz: https://doaj.org/article/559b3f8416ed47f4ba8dbc1a517b7989
Zobrazit plný text záznamu
4
Akademický článek
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Autor: Harsha Ranganath, Amit L. Jain, Justin R. Smith, Julie Ryder, Amina Chaudry, Emily Miller, Felicia Hare, Poojitha Valasareddy, Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, Tyler J. Nielsen, Janice Mullins, Douglas T. Ross, David R. Gandara, Gregory A. Vidal
Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Immune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless, only a subset of patients benefit, even when selected based on approved biomarkers such as P
Externí odkaz: https://doaj.org/article/ca410bdf72ce41f5b615b14aab591ed1
Zobrazit plný text záznamu
5
Akademický článek
Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab
Autor: David L. Saltman, Tyler J. Nielsen, Davide Salina, David R. Hout, Frank B. McMahon, Boris R. Valev, Michael Huk, Pranil K. Chandra, Jeremy Spille, Robert S. Seitz, Brock L. Schweitzer
Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Single-agent immune checkpoint inhibitor therapy in advanced non-small cell lung cancer can significantly prolong progression-free and overall survival when compared with cytotoxic chemotherapy. Here, we report a case of newly diagnosed adenocarcinom
Externí odkaz: https://doaj.org/article/7b2d91b2251644438a237f9b577cb0d2
Zobrazit plný text záznamu
6
Akademický článek
A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
Autor: Tyler J. Nielsen, Brian Z. Ring, Robert S. Seitz, David R. Hout, Brock L. Schweitzer
Publikováno v: Heliyon, Vol 7, Iss 3, Pp e06438- (2021)
Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (
Externí odkaz: https://doaj.org/article/58ad701311c34bcc966073d484c3d0d5
Zobrazit plný text záznamu
8
Data from TLE3 Expression Is Associated with Sensitivity to Taxane Treatment in Ovarian Carcinoma
Autor: Warner K. Huh, Neville F. Hacker, Philippa M. O'Brien, Robert L. Sutherland, Robert S. Seitz, Doug T. Ross, Brian Z. Ring, Goli Samimi
Background: We have previously shown that transducin-like enhancer of split 3 (TLE3) is associated with outcome specifically in patients with taxane-treated breast cancer and not in patients treated with anthracycline-based regimens without a taxane.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9235514197c1eb541c1efc2d97736565
https://doi.org/10.1158/1055-9965.c.6515362.v1
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje